Drugs / Alpibectir
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT07350174 | Mar 2026 → Mar 2028 expected | meningeal tuberculosis | BioVersys AG | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT06748937 | Mar 2025 → Mar 2026 overdue | pulmonary tuberculosis | TASK Applied Science | Recruiting | No outcome recorded |
| Phase 2 | NCT05807399 | Apr 2023 → Oct 2027 expected | pulmonary tuberculosis | Michael Hoelscher | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Alpibectir | “Alpe375 (alpibectir (30 mg/day), ethionamide (375 mg/day))” NCT07350174 ↗ |
| Known as | GSK3729098 | “Alpibectir (GSK3729098)” NCT05807399 ↗ |
| Route | Oral | “All treatments will be administered orally (PO) on days 1-14.” NCT06748937 ↗ |